StreetInsider.com News Articles

Form 4 MEXCO ENERGY CORP For: Mar 05 Filed by: DECKER THOMAS H

Mon, 09 Mar 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20260309/26133857.html

Form 4 MEXCO ENERGY CORP For: Mar 05 Filed by: DECKER THOMAS H

Mon, 09 Mar 2026 19:53:00 -0400

si-local-file:///var/storage/secattach/20260309/26133857.html

Form 144 MEXCO ENERGY CORP Filed by: DECKER THOMAS H

Tue, 03 Mar 2026 13:19:00 -0400

si-local-file:///var/storage/secattach/20260303/26099695.html

Form 144 MEXCO ENERGY CORP Filed by: DECKER THOMAS H

Tue, 03 Mar 2026 13:19:00 -0400

si-local-file:///var/storage/secattach/20260303/26099695.html

Form 8-K MEXCO ENERGY CORP For: Feb 10

Tue, 10 Feb 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260210/25976673.html

Form 8-K MEXCO ENERGY CORP For: Feb 10

Tue, 10 Feb 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260210/25976673.html

Form 10-Q MEXCO ENERGY CORP For: Dec 31

Tue, 10 Feb 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260210/25976640.html

Form 10-Q MEXCO ENERGY CORP For: Dec 31

Tue, 10 Feb 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260210/25976640.html

Mexco Energy Corporation Reports Financial Results for first Six Months

Wed, 12 Nov 2025 16:53:00 -0400

MIDLAND, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) today reported net income of $565,457, or $0.27 per diluted share, for the six months ending September 30, 2025.

Operating revenues in the first six months of fiscal 2026 were $3,548,919, an increase of 2% when compared to the first six months of fiscal 2025. This increase was primarily due to an increase in revenues from our most recent limited liability company investment, an increase in average gas prices, and an increase in oil and natural gas production volumes partially offset

Mexco Energy Corporation Reports Financial Results for first Six Months

Wed, 12 Nov 2025 16:53:00 -0400

Mexco Energy Corporation Reports Financial Results for first Six Months

Wed, 12 Nov 2025 16:53:00 -0400

Mexco Energy Corporation Reports Financial Results for first Six Months

Wed, 12 Nov 2025 16:53:00 -0400

Form 8-K MEXCO ENERGY CORP For: Nov 12

Wed, 12 Nov 2025 16:45:00 -0400

si-local-file:///var/storage/secattach/20251112/25599169.html

Form 8-K MEXCO ENERGY CORP For: Nov 12

Wed, 12 Nov 2025 16:45:00 -0400

si-local-file:///var/storage/secattach/20251112/25599169.html

Form 10-Q MEXCO ENERGY CORP For: Sep 30

Wed, 12 Nov 2025 16:44:00 -0400

si-local-file:///var/storage/secattach/20251112/25599150.html

Form 10-Q MEXCO ENERGY CORP For: Sep 30

Wed, 12 Nov 2025 16:44:00 -0400

si-local-file:///var/storage/secattach/20251112/25599150.html

Form 8-K MEXCO ENERGY CORP For: Sep 11

Thu, 11 Sep 2025 14:52:00 -0400

si-local-file:///var/storage/secattach/20250911/25324878.html

Form 8-K MEXCO ENERGY CORP For: Sep 11

Thu, 11 Sep 2025 14:52:00 -0400

si-local-file:///var/storage/secattach/20250911/25324878.html

Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

Wed, 27 Aug 2025 17:30:00 -0400

Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence

Highlights

Binding term sheet signed to acquire key assets and IP of AusCann Group Holdings Ltd.

Assets include Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, EU-GMP manufacturing, and German pharma distribution.

Strengthens Argent's clinical pipeline, IP portfolio, and European infrastructure.

Adds audited assets supporting Argent's planned dual U.S. national exchange listing.

AC8 Asset Acquisition to Transform Growth

NEW YORK and SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the

Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

Wed, 27 Aug 2025 17:30:00 -0400

Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence

Highlights

Binding term sheet signed to acquire key assets and IP of AusCann Group Holdings Ltd.

Assets include Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, EU-GMP manufacturing, and German pharma distribution.

Strengthens Argent's clinical pipeline, IP portfolio, and European infrastructure.

Adds audited assets supporting Argent's planned dual U.S. national exchange listing.

AC8 Asset Acquisition to Transform Growth

NEW YORK and SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the

Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

Wed, 27 Aug 2025 17:30:00 -0400

Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence

Highlights

Binding term sheet signed to acquire key assets and IP of AusCann Group Holdings Ltd.

Assets include Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, EU-GMP manufacturing, and German pharma distribution.

Strengthens Argent's clinical pipeline, IP portfolio, and European infrastructure.

Adds audited assets supporting Argent's planned dual U.S. national exchange listing.

AC8 Asset Acquisition to Transform Growth

NEW YORK and SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the

Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

Wed, 27 Aug 2025 17:30:00 -0400

Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence

Highlights

Binding term sheet signed to acquire key assets and IP of AusCann Group Holdings Ltd.

Assets include Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, EU-GMP manufacturing, and German pharma distribution.

Strengthens Argent's clinical pipeline, IP portfolio, and European infrastructure.

Adds audited assets supporting Argent's planned dual U.S. national exchange listing.

AC8 Asset Acquisition to Transform Growth

NEW YORK and SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the

Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

Wed, 27 Aug 2025 17:30:00 -0400

Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence

Highlights

Binding term sheet signed to acquire key assets and IP of AusCann Group Holdings Ltd.

Assets include Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, EU-GMP manufacturing, and German pharma distribution.

Strengthens Argent's clinical pipeline, IP portfolio, and European infrastructure.

Adds audited assets supporting Argent's planned dual U.S. national exchange listing.

AC8 Asset Acquisition to Transform Growth

NEW YORK and SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the

Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

Wed, 27 Aug 2025 17:30:00 -0400

Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence

Highlights

Binding term sheet signed to acquire key assets and IP of AusCann Group Holdings Ltd.

Assets include Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, EU-GMP manufacturing, and German pharma distribution.

Strengthens Argent's clinical pipeline, IP portfolio, and European infrastructure.

Adds audited assets supporting Argent's planned dual U.S. national exchange listing.

AC8 Asset Acquisition to Transform Growth

NEW YORK and SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the

Argent is Growing Through M&A: Projected Merged Company Value of $100M in AC8 Asset Acquisition

Wed, 27 Aug 2025 17:30:00 -0400

Acquisition Expands Clinical Pipeline, Strengthens IP Portfolio, and Grows EU Presence

Highlights

Binding term sheet signed to acquire key assets and IP of AusCann Group Holdings Ltd.

Assets include Neuvis® drug delivery platform, FDA-facing epilepsy pre-clinical data, EU-GMP manufacturing, and German pharma distribution.

Strengthens Argent's clinical pipeline, IP portfolio, and European infrastructure.

Adds audited assets supporting Argent's planned dual U.S. national exchange listing.

AC8 Asset Acquisition to Transform Growth

NEW YORK and SYDNEY, Aug. 27, 2025 /PRNewswire/ -- Argent BioPharma Ltd (ASX: RGT) has signed a binding term sheet to acquire the